JAZZ (NASDAQ) - Jazz Pharmaceuticals PLC

Exchange: USA Stocks • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B4Q5ZN47
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Web URL: https://www.jazzpharma.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for JAZZ (NASDAQ) - Jazz Pharmaceuticals PLC


Market Cap in USD 8,324m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2007-06-01


Fundamental 1.96
Dividend -
Performance 5y -1.02
Rel. Performance vs Sector -0.86
Analysts 4.38
Fair Price Total Ret. 120.36
Fair Price DCF todo


Growth TTM 1.47%
CAGR 5y -4.46%
CAGR / Mean Drawdown 5y -0.22
Sharpe Ratio TTM -0.17
Alpha vs SP500 TTM -12.91
Beta vs SP500 5y weekly 0.74
CAPM 6.96%
Average Daily Range 2m 1.82%
Reversal Oscillator 36.46
Volatility GJR Garch 1y 32.27%
Price / SMA 50 -1.82%
Price / SMA 200 -5.47%
Current Volume 347.5k
Average Volume 20d 477.6k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%